Long COVID Drug Pipeline — PatSnap Eureka
Long COVID Drug Pipeline: Autonomic, Microclot & Immune Dysregulation Approaches
Long COVID (PASC) affects an estimated 65–100 million people globally with no approved pharmacological treatment. Explore the investigational targets — from fibrin amyloid microclots to complement inhibition — shaping the emerging therapeutic landscape.
Four Intersecting Pathological Axes Drive Long COVID
Long COVID — formally designated Post-Acute Sequelae of SARS-CoV-2 infection (PASC) — is a multisystem syndrome characterized by persistent fatigue, cognitive impairment, dysautonomia, and coagulopathy lasting months to years after acute infection. Its heterogeneous pathophysiology spans at least four intersecting axes, each representing a distinct cluster of investigational therapeutic targets.
The immune-inflammatory axis is anchored by the IL-1β, IL-6, and TNF-α cytokine triad, confirmed as chronically elevated in a large cohort study (n=8,077) at a mean 8-month follow-up — and notably not driven by autoantibodies. Research from Erasmus MC further characterized monocyte-driven inflammation with increased CD8+ T-lymphocytes in fatigued Long COVID patients.
The coagulation axis centers on fibrin amyloid microclots — a feature unique to Long COVID blood, invisible to standard D-dimer and CRP assays — identified by the Stellenbosch University/University of Liverpool group. These microclots entrap α-2-antiplasmin, VWF, platelet factor 4, and serum amyloid A, inhibiting fibrinolysis and promoting microvascular occlusion. Learn more about PatSnap's life sciences intelligence for tracking this emerging target class.
The autonomic dysfunction axis encompasses HRV abnormalities, sympathetic/parasympathetic imbalance, and ergoreflex overstimulation. A retrospective study of 152 patients demonstrated that COVID infection worsens pre-existing autonomic dysfunction, and a 12-month longitudinal study from Newcastle University confirmed objective autonomic recovery over time.
The complement system — spanning classical, alternative, and terminal pathway activation markers — was identified by Cardiff University (2023) as significantly dysregulated in Long COVID plasma, serving dual roles as both a diagnostic predictor and a therapeutically amenable target.
Long COVID Drug Pipeline: Evidence Stage & Target Distribution
Visualising the 11 investigational therapeutic modalities identified across retrieved literature, mapped by evidence stage and pathological axis.
Therapeutic Modalities by Evidence Stage
Of 11 modalities identified, only 2 have RCT-level evidence (both nutraceuticals). The majority remain at preclinical or mechanistic hypothesis stage.
Investigational Targets by Pathological Axis
The immune-inflammatory axis attracts the most investigational activity, followed by the coagulation/microclot and complement axes.
Clinical Evidence Ladder: Long COVID Therapeutic Interventions by Study Size
Mapping interventions by patient cohort size reveals that the largest evidence bases come from retrospective autonomic studies and nutraceutical RCTs, not molecular therapeutics.
11 Investigational Approaches Across the Long COVID Pipeline
From triple anticoagulant therapy targeting fibrin microclots to complement inhibition and autonomic neuromodulation — here are the key modalities documented in the retrieved literature.
Triple Anticoagulant/Antiplatelet Therapy
The Stellenbosch University group advanced a combination of clopidogrel + aspirin (antiplatelet) plus apixaban (anticoagulant) targeting the dual pathology of fibrin amyloid microclots and platelet hyperactivation. A South African cohort reported resolution of persistent Long COVID symptoms. Fibrin amyloid microclots — resistant to normal plasmin-mediated fibrinolysis due to elevated α-2-antiplasmin entrapment — represent a pathology invisible to standard D-dimer and CRP assays. Explore PatSnap life sciences analytics for anticoagulant patent landscapes.
Stellenbosch University / U. Liverpool · 2021–2022IL-6 Receptor Blockade + Antiviral (Tocilizumab + Nirmatrelvir)
A Northwestern University case report demonstrated that nirmatrelvir/ritonavir combined with tocilizumab (IL-6R blockade) in a rheumatoid arthritis patient with confirmed SARS-CoV-2 antigen persistence produced transient reduction of antigen burden and PASC symptoms — providing proof-of-concept for targeting viral reservoir persistence alongside cytokine suppression. The IL-1β, IL-6, and TNF-α triad was confirmed as chronically elevated in an independent n=8,077 cohort at 8-month follow-up.
Northwestern University · 2022Complement Pathway Inhibition
Cardiff University (2023) quantified activation across all three complement pathways — classical (C1s-C1INH), alternative (Ba, iC3b), and terminal (C5a, TCC) — in Long COVID plasma and explicitly identified complement inhibition as "therapeutically amenable." Complement markers may serve dual roles as diagnostic predictors and treatment response biomarkers. No specific complement inhibitor has reached clinical trial status in the retrieved dataset. PatSnap Analytics can map complement inhibitor patent activity globally.
Cardiff University · 2023Autonomic Neuromodulation
The Franklin Cardiovascular Autonomic Dysfunction and POTS Center conducted a retrospective 152-patient series using autonomic testing-guided parasympathetic/sympathetic rebalancing for Long COVID dysautonomia. A 12-month longitudinal study from Newcastle University confirmed that objective autonomic measures improve over time, validating autonomic endpoints as trial outcome measures. Autonomic recovery correlates with objective peripheral muscle improvement, suggesting synergy with structured exercise rehabilitation.
Franklin Cardiovascular Center / Newcastle University · 2022–2023Kynurenine Pathway (KMO) Inhibition
Activation of the indoleamine-dioxygenase (IDO) / tryptophan catabolite (TRYCAT) pathway — yielding elevated kynurenine, quinolinic acid, and depressed tryptophan — is a mechanistic driver of neuropsychiatric fatigue and anxiety in Long COVID. Kynurenine 3-monooxygenase (KMO) inhibition is proposed to reduce neuroinflammation by redirecting tryptophan catabolism away from neurotoxic quinolinic acid. Low tryptophan and elevated kynurenine/TRP ratio characterize a severe Long COVID endophenotype affecting approximately 22% of patients in one cohort.
University of Leicester / Chulalongkorn University · 2021–2023Short Corticosteroid Course (Prednisone)
A 4-day prednisone course in 9 persistent symptom patients (Instituto de Investigación Sanitaria 12 de Octubre, Madrid, 2021) reduced immunological alterations, normalizing monocyte activation, PD-1 exhaustion markers, and Th1 predominance. While the evidence base is small, this pre-/post-treatment immunophenotyping study provides measurable immune normalization data as a proof-of-concept signal for anti-inflammatory intervention.
Instituto 12 de Octubre, Madrid · 2021Long COVID Investigational Pipeline: All Modalities at a Glance
Comprehensive table of all 11 investigational therapeutic modalities identified, with target, institution, and evidence stage.
Map the Long COVID Patent Landscape
PatSnap Eureka surfaces patent filings, assignee activity, and literature signals across all therapeutic axes — in seconds.
Combination Strategies & Novel Approaches in the Long COVID Pipeline
Retrieved results signal several combination strategies and structurally novel approaches, though clinical validation remains early or absent across all.
Antiviral + IL-6 Blockade Combination
The Northwestern University case report suggests combination viral reservoir clearance (nirmatrelvir/ritonavir) with cytokine suppression (tocilizumab) may be required in patients with confirmed antigen persistence — addressing both the upstream driver and the downstream inflammatory cascade simultaneously.
Gut Microbiome Restoration + Immune Modulation
Multiple retrieved results document intestinal dysbiosis persisting after SARS-CoV-2 recovery. Probiotic-based approaches targeting gut-brain axis dysfunction — including the SCG3 biomarker for brain-gut disturbance identified in Imperial College Healthcare phenotyping data — may complement immune-targeted therapies. The DELong#3 phase 3 pilot RCT of VSL#3 probiotic was initiated.
KMO Inhibition + Anti-Inflammatory Combination
IDO activation and resulting TRYCAT accumulation mediate both immune dysregulation and neuropsychiatric symptoms. Retrieved results suggest combining KMO inhibitors with anti-inflammatory agents could address multiple symptom clusters simultaneously — fatigue, anxiety, and cognitive impairment — in the approximately 22% of patients with severe TRYCAT endophenotype.
Autonomic Neuromodulation + Exercise Rehabilitation
Retrieved results from Newcastle University suggest that autonomic recovery correlates with objective peripheral muscle improvement over 12 months, implying that targeted autonomic therapy alongside structured exercise rehabilitation may represent a synergistic approach — with objective autonomic endpoints now validated as trial outcome measures.
Who Is Driving Long COVID Research? Key Institutions & Commercial Players
Activity in this dataset is predominantly literature-driven (academic), with no patent filings identified among retrieved records — a notable signal reflecting either the early-stage nature of PASC drug development or gaps in search coverage. This creates a significant commercial white space, particularly around the microclot biology axis.
The Stellenbosch University / University of Liverpool collaboration (Etheresia Pretorius and Douglas Kell) represents the most coherent research program in the dataset, spanning fibrin amyloid microclots, α-2-antiplasmin, platelet pathology, and triple-anticoagulant therapy across 2021–2022. PatSnap Analytics can identify whether this group has filed associated IP.
Martin-Luther-University Halle-Wittenberg anchors the cytokine triad evidence in a large digital epidemiology cohort (n=8,077 + 333 validation). Erasmus MC conducted immunological profiling of fatigued vs. non-fatigued Long COVID patients. Cardiff University (2023) positions as a key contributor to complement biomarker and therapeutic target identification.
On the commercial side, EpicentRx Inc. (La Jolla, CA) is the only commercial biopharma entity proposing a specific molecular mechanism (TGF-β inhibition). PrecisionLife Ltd. (UK) applies combinatorial genomics to Long COVID genetic risk factors — identifying shared pathways with WHO-recognized ME/CFS — signaling IP-generating activity. The Royal College of Surgeons in Ireland contributes VWF/ADAMTS-13 endotheliopathy data relevant to anti-thrombotic pipeline development. Track commercial assignee filings with PatSnap customer intelligence tools.
The Franklin Cardiovascular Autonomic Dysfunction and POTS Center is the single institution in this dataset with a dedicated Long COVID autonomic testing and neuromodulation program — a potential first-mover position in a clinically underserved area.
Long COVID Drug Pipeline — Key Questions Answered
Long COVID (Post-Acute Sequelae of SARS-CoV-2 infection; PASC) affects an estimated 65–100 million people globally and is characterized by persistent fatigue, cognitive impairment, dysautonomia, and coagulopathy lasting months to years after acute SARS-CoV-2 infection.
Long COVID is a multisystem syndrome driven by at least four intersecting pathological axes: (1) persistent immune dysregulation and cytokine elevation, (2) fibrin amyloid microclot formation and platelet hyperactivation, (3) autonomic nervous system dysfunction including parasympathetic/sympathetic imbalance and postural orthostatic tachycardia, and (4) microvascular endotheliopathy with failed fibrinolysis.
Two completed randomized controlled trials are documented — the systemic enzyme/probiotic combination (n=200, 14 days) and the adaptogen combination ADAPT-232 (n=100, 14 days) — both reporting statistically significant reductions in fatigue on validated scales. A phase 3 pilot RCT of VSL#3 probiotic was initiated (DELong#3). These represent the most advanced clinical evidence in the retrieved dataset, though all involve nutraceuticals rather than approved or investigational molecular therapeutics.
Stellenbosch University researchers identified fibrin(ogen) amyloid microclots and platelet hyperactivation as a central pathological finding in Long COVID blood, with microclots entrapping inflammatory molecules including α-2-antiplasmin, Von Willebrand Factor (VWF), platelet factor 4, and serum amyloid A — inhibiting fibrinolysis and promoting microvascular occlusion.
No approved pharmacological treatment for Long COVID is documented in the retrieved results. Multiple reviews explicitly state no effective pharmacological interventions have been established.
A 2023 Cardiff University paper identified complement dysregulation — spanning classical (C1s-C1INH complex), alternative (Ba, iC3b), and terminal pathway (C5a, TCC) activation markers — as significantly elevated in Long COVID plasma, establishing the complement cascade as a tractable therapeutic target. Complement markers also serve as predictive biomarkers and potential treatment response indicators.
Still have questions about the Long COVID pipeline? Let PatSnap Eureka search the evidence for you.
Ask Eureka AI About Long COVID TargetsAccelerate Your Long COVID Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to surface patent signals, map therapeutic targets, and identify white spaces across emerging disease areas including PASC.
References
- The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19 Martin-Luther-University Halle-Wittenberg · 2022
- Severe fatigue as symptom of long COVID is characterized by increased expression of inflammatory genes in monocytes Erasmus MC · 2022
- Complement dysregulation is a predictive and therapeutically amenable feature of long COVID Cardiff University · 2023
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications Stellenbosch University · 2022
- Long COVID and the Autonomic Nervous System: The Journey from Dysautonomia to Therapeutic Neuro-Modulation Franklin Cardiovascular Center · 2022
- Long COVID (PASC) Is Maintained by a Self-Sustaining Pro-Inflammatory TLR4/RAGE-Loop Newal R&D Ltd. · 2022
- Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in Long COVID University of Kufa · 2023
- Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/PASC can resolve their persistent symptoms Stellenbosch University · 2021
- Persistent clotting protein pathology in Long COVID/PASC is accompanied by increased levels of antiplasmin University of Liverpool · 2021
- Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence Northwestern University · 2022
- A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID Instituto de Investigación Sanitaria 12 de Octubre, Madrid · 2021
- Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19 NIH / NIAAA · 2021
- Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? University of Leicester · 2021
- A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue Pulmonary Fibrosis Now · 2021
- Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial National Family Medicine Training Centre, Georgia · 2022
- Recovery of Neurophysiological Measures in Post-COVID Fatigue – a 12-month Longitudinal Follow-up Study Newcastle University · 2023
- Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction Royal College of Surgeons in Ireland · 2022
- Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis PrecisionLife Ltd. · 2023
- Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease Imperial College Healthcare NHS Trust · 2023
- Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment Fukuoka University · 2022
- WHO: Post COVID-19 condition (Long COVID) World Health Organization
- NIH RECOVER Initiative: Researching COVID to Enhance Recovery National Institutes of Health
- Newcastle University: Post-COVID Research Programme Newcastle University
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.